Cargo agrees to Concentra buyout after trial setback, layoffs

The cell therapy developer, which raised nearly $500 million in 2023 on the promise of its CAR-T work, has floundered since a safety setback forced it to scrap its lead candidate.

By Ned Pagliarulo • July 8, 2025

Protein degraders: chasing undruggable targets

Some two dozen biotech developers of PROTACs, molecular glues and other types of protein-degrading drugs have sprung up over the past two decades.

By Gwendolyn Wu • Updated July 9, 2025

Explore the Trendline➔

Cell therapy

The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases.

By BioPharma Dive staff

After delay, Kalvista wins FDA OK for drug to treat rare swelling disorder

The company had blamed FDA "resource constraints" for the delay, while a rival drug for hereditary angioedema received an on-time approval.

By Jonathan Gardner • July 7, 2025

Study results boost Cogent’s case for rare disease drug

One analyst described Cogent’s data as a “home run scenario” for bezuclastinib, which the company is positioning as a competitor to Blueprint Medicines’ Ayvakit.

By Gwendolyn Wu • July 7, 2025

[Podcast] Trial Trailblazers: Behind clinical breakthroughs

Explore how innovative clinical trials are transforming treatments for children with rare diseases in this compelling podcast.

By BioPharma Dive's studioID • July 7, 2025

Regeneron bispecific approved for myeloma; Concentra to buy IGM

Lynozyfic is one of two bispecific antibodies Regeneron hopes will lift its oncology business. Meanwhile, IGM is the latest struggling biotech to agree to a buyout deal from Concentra.

By BioPharma Dive staff • July 2, 2025

Acadia CEO sets sights on ‘much more assertive’ deals to invigorate pipeline

Industry veteran Catherine Owen Adams expects external innovation will be key to getting the brain-focused drug developer to “the next level.”

By Jacob Bell • July 2, 2025

Sodium channel blockers for pain: New opportunities after Vertex’s ‘watershed’ moment

The success of Vertex's opioid alternative Journavx could aid a group of biotechs that aim to take a similar path with NaV1.8 and NaV1.7 inhibitors.

By Jacob Bell • July 1, 2025

Sage to lay off most staff amid Supernus buyout

The biotech, which agreed to be bought by Supernus after clinical and commercial struggles, plans to lay off 338 employees by late August.

By Gwendolyn Wu • June 30, 2025

Moderna flu shot outperforms marketed vaccines in large late-stage trial

The mRNA drug developer said it will begin discussing approval with the FDA, which has adopted stricter vaccine review standards.

By Jonathan Gardner • June 30, 2025

AbbVie to buy CAR-T developer Capstan in deal worth up to $2.1B

The acquisition will expand AbbVie's exploration of in vivo CAR-T therapy, an ambitious approach that could sidestep some of the difficulties presented by current cell treatments.

By Ned Pagliarulo • June 30, 2025

Biocryst sells Europe business; Peter Marks criticizes new FDA vaccine rules

Biocryst is offloading part of its business for $250 million. Meanwhile, the former FDA leader took issue with a new policy for COVID-19 shots.

By BioPharma Dive staff • June 27, 2025

Vor, with new CEO, changes course to target autoimmune disease

The biotech, which earlier this year laid off nearly all of its staff, also announced a PIPE that will hand it $175 million in new funding.

By Gwendolyn Wu • June 26, 2025

Acadia’s ‘very bullish’ sales forecast restores some confidence on Wall Street

The brain drug developer is now saying that its two marketed products could ultimately bring in $2 billion annually, and its pipeline may one day add another $12 billion in sales each year.

By Jacob Bell • June 26, 2025

Kymera adds Gilead as research partner, while advancing new candidate with Sanofi

The biotech will work on molecular glue degraders with Gilead in a new deal. Existing partner Sanofi changed its focus to a new drug prospect, meanwhile.

By Gwendolyn Wu • June 25, 2025

FDA investigating Elevidys safety; Nektar shares spike on eczema data

The agency said it will evaluate whether regulatory action is needed after investigating the deaths of two patients treated with Sarepta's therapy.

By BioPharma Dive staff • June 24, 2025

Lexeo to help launch spinout around RNA drugs for the heart

Backed by Perceptive Xontogeny Venture Funds and venBio Partners, the new biotech will make genetic medicines that don’t rely on viral vectors.

By Gwendolyn Wu • June 24, 2025

Chasing rivals, Nuvalent to seek approval of targeted lung cancer drug

New study results position Nuvalent to bring forward what it claims is a differentiated treatment for ROS1-positive lung cancer, a crowded indication with uncertain sales potential.

By Ben Fidler • June 24, 2025

Cidara stock soars as antiviral drug succeeds in flu study

Company shares doubled on Phase 2 study results suggesting its drug could become an alternative to vaccines for flu prevention.

By Delilah Alvarado • June 23, 2025

Illumina to buy SomaLogic in deal worth up to $425M

Illumina expects that adding SomaLogic will aid its “multiomics” business strategy and strengthen the value of its gene sequencing products.

By Susan Kelly • June 23, 2025

Prothena to lay off majority of staff; Zealand shares obesity drug data

Prothena will cut 63% of its workforce and evaluate a “range of business options.” Elsewhere, Zealand revealed data for a dual-acting obesity drug and Biogen kicked off a new late-stage trial.

By BioPharma Dive staff • June 20, 2025

A longer ‘winter’: Public funding slowdown heightens pressure on biotech startups

A dramatic pullback in public biotech investment catalyzed by economic and regulatory upheaval is putting even more stress on startups navigating a yearslong downturn.

By Gwendolyn Wu • June 20, 2025

FDA approves twice-yearly shot of Gilead drug for HIV prevention

The clearance ushers in a closely-watched launch for Gilead, which aims to show a long-acting injection can upend a market dominated by oral medicines. 

By Delilah Alvarado • June 18, 2025

Scholar Rock drug preserves muscle in obesity trial

While the results were an important proof point for so-called anti-myostatin drugs, Scholar Rock executives indicated the company may look for a partner in obesity while focusing on rare diseases.

By Kristin Jensen • June 18, 2025

Draig, a brain drug startup, debuts with $140M to treat depression

The funds will support Phase 2 testing of a drug the company believes to be able to safely home in on AMPA receptors, an emerging but unproven depression target.

By Gwendolyn Wu • June 18, 2025